Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Hospira, Inc.
483
•Hospira, Inc.•June 17, 2011

Hospira, Inc. – FDA 483, Jun 17, 2011

Record Details

This FDA Form 483, issued to Hospira, Inc., a pharmaceutical and device manufacturer and gamma irradiator in Rocky Mount, NC, following an inspection from May 16 to June 17, 2011, details 18 observations of objectionable conditions.

Key issues include: * **Quality System Deficiencies:** No written stability testing program for drug products, specifically lacking routine sterility and container-closure integrity testing. The "Maintenance of Sterility" (MOS) program lacks justification for its representative sampling. * **Quality Control Unit Failures:** Contradictory instructions in MOS procedures and inadequate review of cross-contamination incidents (Dexmedetomidine HCL Injection). * **Investigation Failures:** Inadequate review of unexplained discrepancies and out-of-specification (OOS) results, including a sterilization failure (Lidocaine Hydrochloride) and a stability failure (Magnesium Sulfate). OOS laboratory results were dismissed without scientific justification (Dopamine HCl, Atropine Sulfate). Investigations did not extend to other potentially affected drug products (Sodium Chloride Injections). * **Contamination Control:** Deficient separate/defined areas and control systems, with bulk APIs (desmopressin, calcitrol) improperly stored and inconsistently coded in inventory. * **Equipment and Facility Issues:** Equipment not of appropriate design or suitably located, leading to operational difficulties and potential contamination (e.g., aseptic fill

Company
Hospira, Inc.
Inspection date
June 17, 2011
Product type
Devices
Office
Atlanta District Office
People
  • Penny H. McCarver
  • Claudette D. Brooks (Vascular Neurologist/Neurohospitalist/Medical Officer)
  • Jason F. Chancey (District Team Leader / District Team Leader Trainer)
View Company Profile

ID · 82896c82-4b42-450b-bb14-c9eb1b79cac1

Violation Codes1
FD&C Act 801(a)(3)

Full citation text and observation details available on the Dashboard.

Other documents for Hospira, Inc.
  • 483 - 2023-11-14November 14, 2023
  • 483 - 2019-11-21November 21, 2019
  • 483 - 2018-02-02February 2, 2018
  • WARNING_LETTER - 2013-11-15November 15, 2013
  • 483 - 2013-03-01March 1, 2013

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Hospira, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.